Marie-Hélène Lafeuille

Education
M.A. and B.A., economics, Université de Sherbrooke
Summary of Experience
Ms. Lafeuille specializes in health economics and outcomes research. She has conducted a wide range of analyses for the investigation of, among other topics, clinical efficacy, safety profile, cost of illness, resource utilization patterns, treatment patterns, and cost-effectiveness in a broad range of disease areas, including oncology, hematology, schizophrenia, asthma, diabetes mellitus, epilepsy, chronic kidney disease, and cardiovascular diseases. Ms. Lafeuille has extensive experience performing retrospective insurance claims database analyses, retrospective electronic medical record and chart review studies, clinical trial data analyses, and systematic literature reviews (including meta-analyses). Her research has been presented at numerous international clinical conferences, and she has published on various health economic topics, including treatment patterns, direct and indirect resource utilization and medical costs, and drug cost-effectiveness, in several peer-reviewed journals, including Neurology, Hypertension, Cancer, and Menopause. Ms. Lafeuille is a member of the International Society of Pharmacoeconomics and Outcomes Research.
-
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
Current Oncology, 2023
2023Sheffield BS, Eaton K, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L, Stevens AL, Ewara EM, Cheema P
HEOR, Epidemiology & Market Access -
Comparison of Clinical Outcomes in Patients with Schizophrenia Following Different Long-Acting Injectable Event-Driven Initiation Strategies
Schizophrenia, 2023
2023Correll C, Benson C, Emond B, Patel C, Lafeuille MH, Lin D, Morrison L, Ghelerter I, Lefebvre P, Mavros P
HEOR, Epidemiology & Market Access -
Respiratory Syncytial Virus-Related Complications and Healthcare Costs among a Medicare-Insured Population in the United States
Open Forum Infectious Diseases, 2023
2023DeMartino JK, Lafeuille MH, Emond B, Rossi C, Wang J, Liu S, Lefebvre P, Krishnarajah G
HEOR, Epidemiology & Market Access -
Real-World Weight Changes in People with Hiv-1 at Risk of Weight Gain (Female, Black or Hispanic) Switching from Integrase Strand Transfer Inhibitors
Journal of Comparative Effectiveness Research, 2023
2023Donga P, Emond B, Shah A, Bookhart BK, Anderson D, Vermette-Laforme M, Rossi C, Lafeuille MH
HEOR, Epidemiology & Market Access -
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
PharmacoEconomics Open, 2023
2023Vanderpoel J, Emond B, Ghelerter I, Milbers K, Lafeuille MH, Lefebvre P, Ellis LA
HEOR, Epidemiology & Market Access -
Incidence of Cardiometabolic Outcomes among People Living with HIV-1 Initiated on Integrase Strand Transfer Inhibitor Versus Non-Integrase Strand Transfer Inhibitor Antiretroviral Therapies: A Retrospective Analysis of Insurance Claims in the United States
Journal of International AIDS Society, 2023
2023Rebeiro PF, Emond B, Rossi C, Bookhart BK, Shah A, Caron-Lapointe G, Lafeuille MH, Donga P
HEOR, Epidemiology & Market Access -
Treatment Persistence among Bio-Naïve Patients with Crohn's Disease Initiated on Ustekinumab or Adalimumab
Current Medical Research and Opinion, 2023
2023Zhdanava M, Ding Z, Manceur AM, Muser E, Lefebvre P, Holiday C, Lafeuille MH, Pilon D
HEOR, Epidemiology & Market Access -
CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Lu X, Emond B, Qureshi Z, He J, Qian Y, Huang Q, Lefebvre P, Lafeuille MH, Jacobs R
HEOR, Epidemiology & Market Access -
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Narezkina A, Akhter N, Lu X, Emond B, Panjabi S, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Choi M
HEOR, Epidemiology & Market Access -
Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study
Journal of Managed Care & Specialty Pharmacy, 2022
2022Rogers KA, Lu X, Emond B, Côté-Sergent A, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
HEOR, Epidemiology & Market Access -
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States
Current Medical Research and Opinion, 2022
2022Liu J, Emond B, Maiese EM, Lafeuille MH, Lefebvre P, Ghelerter I, Wu C, Hurteau JA, Thaker PH
HEOR, Epidemiology & Market Access -
Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy
Infectious Diseases and Therapy, 2022
2022McComsey GA, Emond B, Shah A, Bookhart BK, Rossi C, Milbers K, Lafeuille MH, Donga P
HEOR, Epidemiology & Market Access -
Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Jayabalan D, Lefebvre P, Rossi A
HEOR, Epidemiology & Market Access -
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
Advances in Therapy, 2022
2022Wu JJ, Lafeuille MH, Emond B, Fakih I, Duh MS, Cappelleri JC, Yin N, Feeney C, Myers DE, DiBonaventura M
HEOR, Epidemiology & Market Access -
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States
Journal of Medical Economics, 2022
2022Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, Benson C
HEOR, Epidemiology & Market Access -
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases
Journal of Managed Care & Specialty Pharmacy, 2022
2022Mesa-Frias M, Rossi C, Emond B, Bookhart B, Anderson D, Drummond S, Wang J, Lefebvre P, Lamerato LE, Lafeuille MH
HEOR, Epidemiology & Market Access -
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer
Journal of Medical Economics, 2022
2022Vanderpoel J, Stevens AL, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L
HEOR, Epidemiology & Market Access -
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
The Oncologist, 2022
2022Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lafeuille MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ
HEOR, Epidemiology & Market Access -
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
Current Medical Research and Opinion, 2022
2022Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P
HEOR, Epidemiology & Market Access -
Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
Journal of Health Economics and Outcomes Research, 2022
2022Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P
HEOR, Epidemiology & Market Access -
Indicators of Suboptimal Treatment and Associated Healthcare Costs among Patients with Crohn's Disease Initiated on Biologic or Conventional Agents
Crohn's & Colitis 360, 2022
2022Pilon D, Ding Z, Muser E, Manceur AM, Vermette-Laforme M, Lafeuille MH, Lefebvre P
HEOR, Epidemiology & Market Access -
Treatment and Comorbidity Burden among People Living with HIV: A Review of Systematic Literature Reviews
Journal of Drug Assessment, 2022
2022Taiwo BO, Romdhani H, Lafeuille MH, Bhojwani R, Milbers K, Donga P
HEOR, Epidemiology & Market Access -
Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax
Current Medical Research and Opinion, 2021
2021Rogers KA, Emond B, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
HEOR, Epidemiology & Market Access -
Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study
Drugs - Real World Outcomes, 2021
2021Gordan L, Chang M, Lafeuille MH, Romdhani H, Paramasivam F, Maiese EM, McKay C
HEOR, Epidemiology & Market Access -
Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
The Journal of Urology, 2021
2021Ryan CJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Freedland SJ
HEOR, Epidemiology & Market Access -
Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
Journal of Managed Care & Specialty Pharmacy, 2021
2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Lefebvre P, Joshi K
HEOR, Epidemiology & Market Access -
Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries
Current Medical Research and Opinion, 2021
2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Joshi K, Lefebvre P
HEOR, Epidemiology & Market Access -
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
CNS Drugs, 2021
2021Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, Mavros P, Lefebvre P
HEOR, Epidemiology & Market Access -
Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data
Current Medical Research and Opinion, 2021
2021Freedland SJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Ryan CJ
HEOR, Epidemiology & Market Access -
Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study
Clinical Therapeutics, 2021
2021Ghosh N, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Huang Q
HEOR, Epidemiology & Market Access -
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
BMC Cancer, 2021
2021Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Lefebvre P, Rossi A
HEOR, Epidemiology & Market Access -
Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
Journal of Health Economics and Outcomes Research, 2021
2021Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille MH, Donga P
HEOR, Epidemiology & Market Access -
Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
Current Medical Research and Opinion, 2020
2020Manceur AM, Durkin M, Kharat A, Bookhart B, Lafeuille MH, Pilon D, Fakih I, Lefebvre P
HEOR, Epidemiology & Market Access -
Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs
Journal of Medical Economics, 2020
2020Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P
HEOR, Epidemiology & Market Access -
Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database
Dermatology and Therapy, 2020
2020Eichenfield LF, DiBonaventura M, Xenakis J, Lafeuille MH, Duh MS, Fakih I, Levenberg M, Cappelleri JC, Sikirica V
HEOR, Epidemiology & Market Access -
An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
Current Medical Research and Opinion, 2020
2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Emond B, Hardy H
HEOR, Epidemiology & Market Access -
Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
Drugs - Real World Outcomes, 2020
2020Patel C, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Tandon N, El Khoury AC
HEOR, Epidemiology & Market Access -
Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
Patient Preference and Adherence, 2020
2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Hardy H, Emond B
HEOR, Epidemiology & Market Access -
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
Current Medical Research and Opinion, 2020
2020Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A
HEOR, Epidemiology & Market Access -
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records
Journal of Diabetes and its Complications, 2019
2019Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M
HEOR, Epidemiology & Market Access -
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
Journal of Medical Economics, 2019
2019Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P
HEOR, Epidemiology & Market Access -
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
PharmacoEconomics - Open, 2019
2019Emond B, Joshi K, El Khoury AC, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P
HEOR, Epidemiology & Market Access -
Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i)
Current Medical Research and Opinion, 2019
2019Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P
HEOR, Epidemiology & Market Access -
Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
Journal of Managed Care & Specialty Pharmacy, 2019
2019Benson C, Emond B, Lefebvre P, Lafeuille MH, Côté-Sergent A, Tandon N, Chow W, Dunn K
HEOR, Epidemiology & Market Access -
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
Clinical Therapeutics, 2019
2019Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R
HEOR, Epidemiology & Market Access -
Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting
Endocrine Practice. 03 2018;24(3):273-287
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
Current Medical Research and Opinion. 2018 Jun;34(6):1125-1133
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Economic burden of treatment failure in chronic lymphocytic leukemia patients
Current Medical Research and Opinion. 2018 Jun;34(6):1135-1142
2018Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M
-
Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin
Current Medical Research and Opinion. 2018 Jun;34(6):1099-1115
2018Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA
HEOR, Epidemiology & Market Access -
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
Cardiovascular Diabetology. Aug 24 2018;17(1):118
2018Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH
HEOR, Epidemiology & Market Access -
Burden of disease associated with a COPD eosinophilic phenotype
International Journal of Chronic Obstructive Pulmonary Disease. 2018 Aug 13;13:2425-2433
2018Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B
HEOR, Epidemiology & Market Access -
Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data
Journal of Asthma. 2018 Oct 16:1-8
2018Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B
HEOR, Epidemiology & Market Access -
Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database
International Journal of Chronic Obstructive Pulmonary Disease. 2018 Sep 12;13:2859-2868
2018Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B
HEOR, Epidemiology & Market Access -
Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
Journal of Managed Care & Specialty Pharmacy. 2018 Oct;24(10):1040-1051
2018Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P
HEOR, Epidemiology & Market Access -
Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans
Clinical Therapeutics. 2018 Sep;40(9):1496-1508
2018DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y
HEOR, Epidemiology & Market Access -
Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting
Current Medical Research and Opinion. Oct 2017;33(10):1763-1772
2017Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N
HEOR, Epidemiology & Market Access -
Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program
Current Medical Research and Opinion. Apr 2017;33(4):713-721
2017Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ
HEOR, Epidemiology & Market Access -
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
BMC Endocrine Disorders. Jun 08 2017;17(1):32
2017Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS
HEOR, Epidemiology & Market Access -
Burden of systemic glucocorticoid-related complications in severe asthma(1)
Current Medical Research and Opinion. Jan 2017;33(1):57-65
2017Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA
HEOR, Epidemiology & Market Access -
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Clinical Therapeutics. Oct 2017;39(10):1972-1985 e1972
2017Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K
HEOR, Epidemiology & Market Access -
Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology
Leukemia and Lymphoma. Aug 2017;58(8):1968-1972
2017Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A
-
Burden of systemic glucocorticoid-related complications in severe asthma
Current Medical Research and Opinion, 2016 Oct 14:1-29
2016Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.
HEOR, Epidemiology & Market Access -
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics
Current Medical Research and Opinion, 2016 04; 32(4): 759-769. e-pub ahead of print 2016/01/12
2016Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.
HEOR, Epidemiology & Market Access, Insurance -
Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Current Medical Research and Opinion, Opin 2016 06; 32(6): 1151-1159. e-pub ahead of print 2016/04/27
2016Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.
HEOR, Epidemiology & Market Access -
Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus
American Journal of Managed Care, Volume 20, Number 1, Supplement - January 2014
2014Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M
HEOR, Epidemiology & Market Access -
Incremental direct and indirect costs of untreated vasomotor symptoms
Menopause, August 25, 2014
2014Sarrel P, Portman D, Lefebvre P, Lafeuille M, Grittner A, Fortier J, Gravel J, Duh MS, Aupperle P
HEOR, Epidemiology & Market Access -
Quality measure attainment in patients with type 2 diabetes mellitus
The American Journal of Managed Care, 2014
2014Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P
HEOR, Epidemiology & Market Access -
Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia
Leuk Lymphoma. 2011 Nov 23
2011Lafeuille M, Vekeman F, Wang S, Kerrigan M, Menditto L, Duh MS
HEOR, Epidemiology & Market Access -
Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
J Med Econ. 2011 Dec 14.
2011Lafeuille M, Bailey R, Vekeman F, Scott McKenzie R, Lefebvre P
HEOR, Epidemiology & Market Access -
Risk of Hepatotoxicity-Related Hospitalizations Among Patients Treated With Opioid-Acetaminophen Combination Prescription Pain Medications
Pain Med. 2010 Nov;11(11):1718-25
2010Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Viau-Latremouille D, Stangle B, Lafeuille M, Greenberg P
HEOR, Epidemiology & Market Access -
Generic antiepileptic drugs and associated medical resource utilization in the United States
Neurology 2010 74: 1566-1574
2010Labiner D, Paradis P, Manjunath R, Duh MS, Lafeuille M, Latremouille-Viau D, Lefebvre P, Helmers S
HEOR, Epidemiology & Market Access -
Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease
The Consultant Pharmacist, 2010
2010Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P
HEOR, Epidemiology & Market Access -
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries
Curr Med Res Opin. 2009; 25(7):1793-1805
2009Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille M, Lefebvre P, Gaudig M, Duh MS
HEOR, Epidemiology & Market Access
-
June 2, 2023
2023 ASCO Annual Meeting to Feature New Outcomes Research from Analysis Group
Event: 2023 ASCO Annual Meeting
Host: American Society of Clinical Oncology (ASCO)
-
October 23, 2023
-
July 25, 2023
-
June 8, 2023
-
December 7, 2022
-
March 29, 2022
